Nimodipine is a second-generation 1,4-dihydropyridine calcium channel blocker. It was initially invented for the management of systemic hypertension. FDA approved the use of nimodipine for the first time in 1988. However, its use is restricted mainly in managing vasospasm following subarachnoid hemorrhage. It also has numerous off-label uses. Nimodipine is available as oral tablets, oral solutions, and intravenous infusion solutions. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of nimodipine, so providers can direct patient therapy successfully in instances where nimodipine provides a benefit to patient care.

**Objectives:**
- Identify the mechanism of action of nimodipine.
- Outline the approved indications and the off-label indications for using nimodipine.
- Review the contraindications of nimodipine.
- Describe interprofessional team strategies for improving care coordination and communication to properly use nimodipine to improve patient outcomes in the varied scenarios where it can be effective.